Xtant Medical Holdings, Inc. has launched its next-generation synthetic bone graft, nanOss Strata, in the United States. The graft, built from hydroxycarbonapatite (HCA), is designed to enhance bioactivity and integration in orthopedic and spinal surgeries. This launch follows the company’s strategic exit from non-core spinal implant assets, signaling a renewed focus on its biologics portfolio.
Why the launch of nanOss Strata signals a sharper orthobiologics focus
The release of nanOss Strata is more than a product announcement. For Xtant Medical Holdings, Inc., a U.S.-based medical technology company focused on surgical solutions for spine and orthopedics, it marks a shift back to its core competency: regenerative biologics. Just days before unveiling Strata, the company completed the divestiture of its Coflex spinal implant business and its international Paradigm Spine operations to Companion Spine. The $19.2 million deal provides liquidity and debt reduction, giving Xtant Medical new breathing room to double down on innovation in biologic implants.
Industry analysts interpret this as a deliberate reorientation toward synthetic grafts and bone substitutes, a category expected to see steady growth due to rising spinal procedure volumes and increasing clinical interest in alternatives to traditional allografts and autografts. The new Strata graft positions Xtant Medical in a highly competitive segment where biomimicry, handling characteristics, and evidence of improved osteoconductivity are emerging as decisive factors.
What differentiates hydroxycarbonapatite from traditional graft materials
At the core of the nanOss Strata value proposition is its shift from conventional hydroxyapatite to hydroxycarbonapatite. While hydroxyapatite is widely used in synthetic grafts, it is relatively insoluble and can result in slower resorption and remodeling. Hydroxycarbonapatite offers higher solubility, which is expected to accelerate graft remodeling and promote more responsive cellular integration. The nanocrystalline structure of HCA used in Strata increases the material’s surface area, potentially improving the attachment and proliferation of bone-forming cells.
This formulation is designed to address a key clinical gap: enhancing the biologic interface between the graft and host bone. The increased solubility and nanoscale architecture could help promote early vascularization and integration—two key factors for successful bone healing in spinal fusion and trauma procedures.
Synthetic bone grafts based on HCA remain underrepresented in the U.S. market, where materials like beta-tricalcium phosphate and standard hydroxyapatite dominate. This may offer Xtant Medical a temporary window of differentiation, especially among surgeons dissatisfied with the remodeling profiles of older graft technologies.
What changes for Xtant Medical’s commercial strategy
The launch of Strata appears to be the first visible move in Xtant Medical’s post-divestiture commercial strategy. With its Coflex assets sold and international units off the balance sheet, the company now has a simplified structure centered around biologics innovation. President and Chief Executive Officer Sean Browne has suggested that this strategic narrowing of focus could help Xtant Medical generate operating cash flow without the need for external capital.
That shift gives Strata elevated importance within the company’s U.S. commercial operations. The product is being rolled out across Xtant Medical’s national distribution network, and its dual-format offering—compression-resistant strips and moldable, prehydrated putty—provides flexibility across a range of spinal and orthopedic procedures.
Biologics generally offer stronger margins and lower inventory risk than hardware systems. They also tend to fare better in hospital purchasing decisions where value committees increasingly prioritize handling, shelf life, and consistency. The moldability and absorption characteristics of Strata make it particularly suitable for use in ambulatory surgery centers, where speed and simplicity are at a premium.
Where clinical and adoption hurdles could emerge
Despite its technical promise, Strata enters a challenging environment. Major players such as Medtronic, Stryker, and DePuy Synthes already offer mature synthetic graft portfolios with strong brand loyalty and published clinical results. Without head-to-head comparative data or peer-reviewed outcomes, Xtant Medical will need to rely on real-world performance and surgeon feedback to build early momentum.
Regulatory pathways for synthetic grafts are relatively straightforward in the United States, often involving 510(k) clearances rather than full premarket approval. However, this regulatory ease also means that clinical differentiation must be proven commercially, not just in the lab. Without robust data on fusion rates or long-term resorption timelines, new entrants like Strata face challenges in convincing hospital systems to adopt at scale.
Clinician preference will also be a gating factor. Surgeons often rely on tactile familiarity and historical performance, and switching to new materials—particularly those with novel chemical properties—may take time. Institutional adoption is likely to depend heavily on whether Strata can prove itself in early use cases, particularly in high-volume spine fusion centers.
What this reveals about post-pandemic biologics market dynamics
The launch of Strata also highlights a broader theme in the orthopedic device sector: the renewed emphasis on biologics following the procedural volatility of the COVID-19 pandemic. Many device companies are shifting away from hardware-heavy portfolios toward regenerative and biologically active platforms that offer flexibility in surgical setting and pricing models.
In this context, Strata aligns with hospital demands for grafts that do not rely on donor tissue or complex storage conditions. Synthetic grafts can reduce procurement friction and support a more scalable logistics model, especially for hospital systems that operate across multiple sites. As minimally invasive and outpatient spine procedures continue to rise, grafts that are moldable, fast-absorbing, and compatible with small incisions may gain further advantage.
If Strata can gain a foothold in this changing procedural environment, it may provide Xtant Medical with a defensible commercial asset that is less vulnerable to pricing compression than traditional spinal hardware.
What competitors and stakeholders are likely to watch next
The entrance of hydroxycarbonapatite-based products into mainstream use could reshape R&D strategies across the synthetic graft landscape. Most legacy products focus on porosity and structural reinforcement. If Strata’s solubility and bioactivity claims hold up in broader use, competitors may be compelled to integrate similar chemical profiles into future iterations.
Hospital buyers and procurement managers will also be watching for clinical outcomes that validate the material’s remodeling efficiency. For many institutions, the promise of better bone integration must be balanced against cost, supply chain stability, and long-term resorption risks.
Clinicians, particularly those operating in outpatient settings, may evaluate Strata’s performance in terms of surgical handling, visualization during procedures, and patient recovery timelines. Ease of use, in this context, could be as influential as any biochemical advantage.
Final outlook: a narrowed play with high biologics upside
Xtant Medical Holdings, Inc. is executing a focused turnaround strategy anchored in biologics. The commercial launch of nanOss Strata offers a chance to validate that pivot. While the synthetic bone graft space remains highly competitive, Strata’s combination of biomimetic design, material science innovation, and surgeon-centric format gives it potential to break through—provided the company can build adoption without overextending its commercial resources.
In the coming quarters, attention will turn to whether the product can generate measurable revenue uplift and demonstrate meaningful clinical differentiation. For now, Strata appears to be a calculated bet on where spinal surgery is headed: more biologics, more outpatient, and more demand for synthetic solutions that can keep pace with evolving procedural complexity.
Inside Xtant Medical’s Strata launch: What sets it apart from legacy bone grafts added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →